.gen Technologies Inc.

The big date is coming for local biotech Arena and its obesity management candidate lorcaserin. October 22 is the date by which the FDA will review their application and determine whether Arena has a viable product or if it’s back to the drawing board. Either way it will be a big turning point for the company, and exciting times [...]

Venture capital continued to flow in modest amounts to San Diego area biotechs last week… Helixis Raises $5.5M | Xconomy Nexus Biosystems Raises $5M | Xconomy …while Arena with its potential obesity blockbuster Lorcaserin made $52.1M on a second stock offering.  Arena shares closed nicely up on the day. Arena Raises $52.1M in Offering | Xconomy Meanwhile, in a bit [...]